A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+ MBC): A trial of the Eastern Cooperative Oncology Group (E1105).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Vanderbilt University, Vanderbilt-Ingram Cancer Center, Dana-Farber Cancer Institute, Fox Chase Cancer Center, Northwestern University, Case Western Reserve University, University of Miami, Sylvester Comprehensive Cancer Center, Mayo Clinic in Florida, Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3010819689